Gan & Lee Pharmaceuticals
甘李藥業股份有限公司
- Listing
- SSE 603087
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| Bofanglutide / GZR18 | Phase 3 in China; Phase 2 in the United States | Not disclosed | 2026-08-10 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-08-10 | A. Menarini International Licensing S.A. | Bofanglutide / GZR18 | EUR 62,000,000 | Not disclosed | ≤ EUR 726,000,000 | Phase 3 in China; Phase 2 in the United States |